EUVIMEDEUVIMED entdecken
Crossref

An Engineered Adeno-Associated Virus Variant Enables Efficient Gene Editing in Human T Cells

Mi Leng, Chunmei Gan, Zhaoyue Zheng, Siwu He, Yu Liu, Lixing Zhou, Rui Cheng, Jiao Zhou, Lin Xiao, Jingya Ye, Zhian Chen, Liangting Xu und 4 weitere

Human Gene Therapy · 2026

DOI: 10.1177/10430342261424779 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Mi Leng und 15 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Geriatrics and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Dependovirus, T-Lymphocytes. Die Arbeit nennt 48 Literaturangaben. Gefördert von: National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CAR-T) cells, created by gene editing systems along with recombinant adeno-associated virus (rAAV), provide a promising strategy for treating leukemia. rAAVs serve as a safe and effective donor template for homology-directed repair because they can avoid integrating into the host genome. However, only a few AAV serotypes can efficiently transduce human primary T cells at low multiplicities of infection (MOIs) with high packaging efficiency. To address this problem, variants derived from an AAV2 peptide library were screened in Jurkat cells and later validated in primary T cells. A high-ranking sequence identified outside the VR-VIII region, NNSKLTV, was discovered after three rounds of selection and was named Tot3. Tot3 demonstrated transduction efficiency similar to AAV2, but at a 27-fold lower MOI. In addition, Tot3 exhibited greater packaging efficiency and reduced thermal stability. Simultaneously, programmed cell death protein 1 (PD-1) knockout and CAR overexpression were achieved in human primary T cells using Tot3, with knockout and knock-in efficiencies reaching up to 70% and 55%, respectively. These CAR-T cells demonstrated significantly enhanced antitumor activity and increased survival times in a mouse model of diffuse B cell lymphoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusT-LymphocytesGenetic EngineeringGene EditingGenetic VectorsHumansCells, CulturedGenetic VariationProgrammed Cell Death 1 ReceptorFemaleAnimalsMice

Stichwörter der Autor:innen

B cell acute lymphocytic leukemiacapsid proteinchimeric antigen receptor T cell immunotherapygene editingrecombinant adeno-associated virus

Substanzen

Programmed Cell Death 1 Receptor

Autor:innen und Institutionen

  • National Clinical Research Center for Geriatrics and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • Sichuan Real & Best Biotech Co., Ltd., Chengdu, China.
  • Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Children's Medicine Key Laboratory of Sichuan Province, Chengdu, China.

Förderung

  • National Key R&D Program of China

Zitieren

APA

Leng, M., Gan, C., Zheng, Z., He, S., Liu, Y., Zhou, L., Cheng, R., Zhou, J., Xiao, L., Ye, J., Chen, Z., Xu, L., Valencia, C. A., Chow, H. Y., Zhang, Y., & Dong, B. (2026). An Engineered Adeno-Associated Virus Variant Enables Efficient Gene Editing in Human T Cells. Human Gene Therapy. https://doi.org/10.1177/10430342261424779

Vancouver

Leng M, Gan C, Zheng Z, He S, Liu Y, Zhou L, et al. An Engineered Adeno-Associated Virus Variant Enables Efficient Gene Editing in Human T Cells. Human Gene Therapy. 2026. doi:10.1177/10430342261424779

BibTeX
@article{Leng2026,
  author = {Leng, Mi and Gan, Chunmei and Zheng, Zhaoyue and He, Siwu and Liu, Yu and Zhou, Lixing and Cheng, Rui and Zhou, Jiao and Xiao, Lin and Ye, Jingya and Chen, Zhian and Xu, Liangting and Valencia, C Alexander and Chow, Hoi Yee and Zhang, Yan and Dong, Biao},
  title = {An Engineered Adeno-Associated Virus Variant Enables Efficient Gene Editing in Human T Cells},
  journal = {Human Gene Therapy},
  year = {2026},
  doi = {10.1177/10430342261424779}
}
Kostenlos starten →